journal
Journals Breast : Official Journal of t...

Breast : Official Journal of the European Society of Mastology

https://read.qxmd.com/read/37783134/the-king-is-in-the-altogether-radiation-therapy-after-oncoplastic-breast-surgery
#1
REVIEW
Orit Kaidar-Person, Birgitte Vrou Offersen, Trine Tramm, Peer Christiansen, Tine Engberg Damsgaard, Ashutosh Kothari, Philip Poortmans
Breast cancer is the most common malignancy, and the majority of the patients are diagnosed at an early disease stage. Breast conservation is the preferred locoregional approach, and oncoplastic breast conservation surgery is becoming more popular. This narrative review aims to discuss the challenges and uncertainties in target volume definition for postoperative radiation after these procedures, to improve radiation therapy decisions and encourage multidisciplinary.
September 25, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37783133/evolving-treatments-and-outcomes-in-her2-positive-metastatic-breast-cancer-data-from-the-gim14-biometa-study
#2
JOURNAL ARTICLE
Massimo Di Maio, Claudia Bighin, Francesco Schettini, Tommaso Ruelle, Laura Marandino, Alessandra Fabi, Carmine De Angelis, Mario Giuliano, Pietro De Placido, Michelino De Laurentiis, Ferdinando Riccardi, Caterina Picotto, Fabio Puglisi, Lucia Del Mastro, Grazia Arpino
BACKGROUND: Treatment for HER2-positive (+) metastatic breast cancer has improved in the last decade. We analyzed treatment changes over time and their impact on patients outcomes in a real-world dataset. METHODS: Data from 637 HER2+ patients with metastatic breast cancer enrolled in the multicenter Italian GIM14/BIOMETA study were retrieved. Progression-free survival (PFS) over time was evaluated according to the type of anti-HER2 therapy, disease onset (de novo vs...
September 25, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37742492/safety-and-efficacy-study-of-oral-metronomic-capecitabine-combined-with-pyrotinib-in-her2-positive-metastatic-breast-cancer-a-phase-ii-trial
#3
JOURNAL ARTICLE
Maiyue He, Jiaxuan Liu, Zijing Wang, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Peng Yuan, Yang Luo, Ying Fan, Hongnan Mo, Bo Lan, Qiao Li, Binghe Xu
PURPOSE: To analyze the safety and efficacy of orally administered metronomic capecitabine plus pyrotinib in HER2 positive metastatic breast cancer (MBC) patients, we conducted a prospective phase II study with a single-arm design. METHODS: HER2 positive patients received oral metronomic capecitabine 500 mg three times a day and pyrotinib 400 mg per day. The primary endpoint was progression-free survival (PFS). Other endpoints included objective response rate (ORR), overall survival (OS), clinical benefit rate (CBR) and safety...
September 20, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37769521/expert-uk-consensus-on-the-definition-of-high-risk-of-recurrence-in-her2-negative-early-breast-cancer-a-modified-delphi-panel
#4
JOURNAL ARTICLE
E R Copson, J E Abraham, J P Braybrooke, D Cameron, S A McIntosh, C O Michie, A F C Okines, C Palmieri, F Raja, R Roylance, S Spensley
BACKGROUND: There is currently no standardised definition for patients at high risk of recurrence of human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC; stages 1-3) after surgery. This modified Delphi panel aimed to establish expert UK consensus on this definition, separately considering hormone receptor (HR)-positive and triple-negative (TN) patients. METHODS: Over three consecutive rounds, results were collected from 29, 24 and 22 UK senior breast cancer oncologists and surgeons, respectively...
September 17, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37741273/neoadjuvant-nivolumab-palbociclib-anastrozole-for-oestrogen-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-primary-breast-cancer-results-from-checkmate-7a8
#5
JOURNAL ARTICLE
Guy Jerusalem, Aleix Prat, Roberto Salgado, Mattea Reinisch, Cristina Saura, Manuel Ruiz Borrego, Petros Nikolinakos, Felipe Ades, Jeiry Filian, Ning Huang, Antonella Mazzei-Abba, Sara M Tolaney
BACKGROUND: Preclinical data suggest synergistic activity with the combination of programmed death-1 and cyclin-dependent kinase 4/6 blockade in oestrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer. The noncomparative phase 1b/2 CheckMate 7A8 study (NCT04075604) evaluated neoadjuvant treatment with nivolumab, palbociclib, and anastrozole in patients with ER+/HER2- breast cancer. Here, we report outcomes from the safety run-in phase. METHODS: Patients with histologically confirmed, untreated ER+/HER2- breast cancer, primary tumour ≥2 cm, ECOG performance status ≤1, and eligible for post-treatment surgery received nivolumab 480 mg intravenously every 4 weeks, palbociclib 125 mg or 100 mg orally once daily for 3 weeks per cycle, and anastrozole 1 mg orally once daily for five 4-week cycles, or until disease progression...
September 15, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37722319/real-world-evidence-of-neoadjuvant-chemotherapy-for-breast-cancer-treatment-in-a-brazilian-multicenter-cohort-correlation-of-pathological-complete-response-with-overall-survival
#6
JOURNAL ARTICLE
Marcelo Antonini, André Mattar, Fernanda Grace Bauk Richter, Gabriel Duque Pannain, Marina Diógenes Teixeira, Andressa Gonçalves Amorim, Odair Ferraro, Reginaldo Coelho Guedes Lopes, Luiz Henrique Gebrim, Juliana Monte Real
OBJECTIVES: We aimed to evaluate the pCR rate in patients receiving NAC for the treatment of breast cancer (BC) in a multicenter cohort in Brazil. Additionally, we aimed to use RWD to assess the impact of pCR on OS and DFS. METHODS: This was a retrospective, multicenter cohort study that included female patients over 18 years of age who were diagnosed with nonmetastatic breast cancer and received NAC. OS and DFS at five years were estimated by the Kaplan‒Meier method...
September 14, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37716023/additional-intraoperative-subpectoral-plane-block-vs-conventional-pain-control-a-comparison-of-shoulder-movement-in-patients-with-mastectomy
#7
JOURNAL ARTICLE
Sivaporn Pondeenana, Chao Saenghirunvattana, Patcharin Intarakhao, Sorasit Inchan, Panuwat Chuemor, Atthakorn Jarusriwanna
PURPOSE: Shoulder pain is common among mastectomy patients, with limiting shoulder mobility and negatively affecting their quality of life. Pectoral nerve blocks (PECs) have demonstrated efficacy in providing postoperative analgesia. We hypothesized that these nerve blocks could improve shoulder movement in patients undergoing mastectomy. METHODS: This prospective, randomized, double-blind controlled trial enrolled female participants diagnosed with breast cancer and scheduled for mastectomy...
September 11, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37713940/contouring-variation-affects-estimates-of-normal-tissue-complication-probability-for-breast-fibrosis-after-radiotherapy
#8
JOURNAL ARTICLE
Tanwiwat Jaikuna, Eliana Vasquez Osorio, David Azria, Jenny Chang-Claude, Maria Carmen De Santis, Sara Gutiérrez-Enríquez, Marcel van Herk, Peter Hoskin, Maarten Lambrecht, Zoe Lingard, Petra Seibold, Alejandro Seoane, Elena Sperk, R Paul Symonds, Christopher J Talbot, Tiziana Rancati, Tim Rattay, Victoria Reyes, Barry S Rosenstein, Dirk de Ruysscher, Ana Vega, Liv Veldeman, Adam Webb, Catharine M L West, Marianne C Aznar
BACKGROUND: Normal tissue complication probability (NTCP) models can be useful to estimate the risk of fibrosis after breast-conserving surgery (BCS) and radiotherapy (RT) to the breast. However, they are subject to uncertainties. We present the impact of contouring variation on the prediction of fibrosis. MATERIALS AND METHODS: 280 breast cancer patients treated BCS-RT were included. Nine Clinical Target Volume (CTV) contours were created for each patient: i) CTV_crop (reference), cropped 5 mm from the skin and ii) CTV_skin, uncropped and including the skin, iii) segmenting the 95% isodose (Iso95% ) and iv) 3 different auto-contouring atlases generating uncropped and cropped contours (Atlas_skin/Atlas_crop)...
September 11, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37696110/unfolding-the-role-of-the-pi3k-akt-mtor-pathway-in-male-breast-cancer-a-pragmatic-appraisal
#9
JOURNAL ARTICLE
Leonor Vasconcelos de Matos, Simona Volovat, Marcio Debiasi, Fatima Cardoso
Breast cancer in men is rare, but a relevant public health issue, yielding a 25% higher risk of mortality comparing to female counterparts. The representation of males in clinical trials has been scarce and treatment decisions are based mainly on extrapolations from data in females. In the setting of estrogen-dependent metastatic disease, the use of everolimus has been seldom reported, although the PI3K/AKT/mTOR pathway seems to be a critical oncogenic driver. This paper dissects hallmark biological features of ER+/HER2-advanced male breast cancer, setting a comprehensive basis to promote personalized care, focusing on the potential of targeting the PI3K/AKT/mTOR pathway...
September 6, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37690320/anti-hormonal-maintenance-treatment-with-the-cdk4-6-inhibitor-ribociclib-after-1st-line-chemotherapy-in-hormone-receptor-positive-her2-negative-metastatic-breast-cancer-a-phase-ii-trial-amica
#10
JOURNAL ARTICLE
Thomas Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk, Nader Hirmas, Kristina Lübbe, Mark-Oliver Zahn, Marcus Schmidt, Carsten Denkert, Ralf Lorenz, Volkmar Müller, Dirk-Michael Zahm, Christoph Mundhenke, Stefan Bauer, Marc Thill, Peter Seropian, Natalie Filmann, Sibylle Loibl
PURPOSE: This phase II study evaluated the impact of adding ribociclib to maintenance endocrine therapy (ET) treatment of physicians' choice following the first palliative chemotherapy in pre- and post-menopausal women with hormone receptor positive (HR+)/human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (mBC). PATIENTS AND METHODS: The initial randomized study design was later amended into a single-arm study, and all subsequent patients received ribociclib and ET...
September 1, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37572626/effect-of-high-dose-radiation-therapy-on-positive-margins-after-breast-conserving-surgery-for-invasive-breast-cancer
#11
JOURNAL ARTICLE
Hyunjung Kim, Tae Gyu Kim, Byungdo Park, Jeong Ho Kim, Si-Youl Jun, Jun Ho Lee, Hee Jun Choi, Chang Shin Jung, Yoon Ju Bang, Hyoun Wook Lee, Jae Seok Lee, Hyun Yeol Nam, Seunghyeon Shin, Sung Min Kim, Haeyoung Kim
PURPOSE: Positive margins after breast-conserving surgery are associated with poor oncological outcomes and warrant additional surgery. This study aimed to evaluate the effectiveness of high-dose radiation therapy for positive margins by comparing local recurrence between patients with positive and negative margins. METHODS: We retrospectively evaluated 550 patients treated with adjuvant radiation therapy after breast-conserving surgery for invasive breast cancer between 2013 and 2019...
August 8, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37566996/adenosquamous-proliferation-in-radial-sclerosing-lesions-histologic-spectrum-and-key-features-in-systematic-review-of-247-lesions
#12
JOURNAL ARTICLE
S Emily Bachert, Virgilius Cornea, Thérèse Bocklage
Adenosquamous proliferation (ASP) is known to occur in the central nidus of radial sclerosing lesions (RSL) of the breast. However, their significance is debated and remains largely unknown. In addition, there is a histologic overlap between ASP and low-grade adenosquamous carcinomas (LGASC). We conducted a large retrospective review of 247 RSLs to evaluate the prevalence of ASP and quantitatively analyze associated histologic features of RSLs including size, stromal cellularity, and presence of chronic inflammation...
August 7, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37562109/breast-cancer-deaths-attributable-to-alcohol-consumption-italy-2015-2019
#13
JOURNAL ARTICLE
Marco Driutti, Luigino Dal Maso, Federica Toffolutti, Giulia Valdi, Ettore Bidoli, Fabiola Giudici, Maria Parpinel, Diego Serraino
A study was conducted to assess the fraction of female breast cancer (BC) deaths attributable to alcohol consumption in Italy. National mortality data for the period 2015-2019 were used along with national estimates of women from the general population exposed to moderate (11-20 gr/day) or heavy (>20 gr/day) alcohol consumption. From 2015 to 2019, 2918 (4.6%) out of 63,428 BC| deaths were attributable to alcohol consumption, including 1269 deaths (2.0%) caused by moderate consumption. Study findings could help stakeholders to prioritize programs aimed at reducing alcohol consumption, and to improve ways to effectively communicate alcohol-related health risks, including moderate consumption...
August 7, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37573653/patient-reported-health-related-quality-of-life-outcomes-following-mastectomy-for-breast-cancer-with-immediate-delayed-or-no-breast-reconstruction-four-year-follow-up-from-a-prospective-cohort-study
#14
JOURNAL ARTICLE
Kathy Dempsey, Erin Mathieu, Meagan Brennan, Kylie Snook, Julia Hoffman, Ian Campbell, Jenni Scarlet, Heather Flay, April Wong, Frances Boyle, Madeleine King, Andrew Spillane
BACKGROUND: Breast reconstruction (BR) improves women's health-related quality of life (HRQOL) following mastectomy for breast cancer, yet factors contributing to improved HRQOL remain unclear. This study aimed to explore the overall impact of mastectomy with or without BR on participants' perceptions of HRQOL over time in a cohort of women with high-risk breast cancer; to examine differences in mean HRQOL scores between immediate BR, delayed BR and no BR groups; to assess the influence of patient characteristics potentially associated with HRQOL scores; and to determine the feasibility of long-term collection of patient-reported outcome measures in clinical settings...
August 6, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37541171/the-natural-history-of-ductal-carcinoma-in-situ-dcis-in-simulation-models-a-systematic-review
#15
REVIEW
Keris Poelhekken, Yixuan Lin, Marcel J W Greuter, Bert van der Vegt, Monique Dorrius, Geertruida H de Bock
OBJECTIVE: Assumptions on the natural history of ductal carcinoma in situ (DCIS) are necessary to accurately model it and estimate overdiagnosis. To improve current estimates of overdiagnosis (0-91%), the purpose of this review was to identify and analyse assumptions made in modelling studies on the natural history of DCIS in women. METHODS: A systematic review of English full-text articles using PubMed, Embase, and Web of Science was conducted up to February 6, 2023...
July 27, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37517154/breast-cancer-survival-and-incidence-of-second-primary-cancers-after-30-years-in-a-randomized-study-of-two-versus-five-years-of-adjuvant-tamoxifen-therapy
#16
JOURNAL ARTICLE
Anna Nordenskjöld, Helena Fohlin, Johan Rosell, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per Malmström, Lisa Rydén, Arne Wallgren, Olle Stål, Bo Nordenskjöld
BACKGROUND: Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. MATERIAL AND METHODS: We studied 30 years outcome of 4124 postmenopausal patients who were randomized to receive (totally) two or five years of adjuvant tamoxifen. RESULTS: After 5 years of follow-up, when tamoxifen treatment was finished in both groups, until 15 years of follow-up, overall mortality (HR 0...
July 25, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37517155/differences-between-the-efficacy-of-her2-2-fish-positive-and-her2-3-in-breast-cancer-during-dual-target-neoadjuvant-therapy
#17
JOURNAL ARTICLE
Wei Chen, Fen-Xiang Li, Da-Lin Lu, Jun Jiang, Junjie Li
INTRODUCTION: This study investigated the differences in efficacy between IHC(2+)/FISH-positive and IHC(3+) in HER2-positive breast cancer (BC) during neoadjuvant chemotherapy (NAC) combined with trastuzumab and pertuzumab. The research also aimed to provide insight into treatment strategies for clinical HER2(2+)/FISH-positive and HER2(3+) BC. MATERIALS AND METHODS: A retrospective analysis was performed on the clinical and pathological data of patients with confirmed diagnoses of invasive BC treated via combined NAC and dual-target therapy who underwent surgery at the Breast Surgery Center of Sichuan Cancer Hospital between June 2019 and June 2022...
July 24, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37499377/direct-and-indirect-effects-of-covid-19-on-short-term-mortality-of-breast-cancer-patients
#18
JOURNAL ARTICLE
Serena Di Cosimo, Silva Ljevar, Annalisa Trama, Alice Bernasconi, Paolo Lasalvia, Maria Carmen De Santis, Vera Cappelletti, Rosalba Miceli, Giovanni Apolone
We studied the COVID-19 impact in newly-diagnosed breast cancer (7,349 patients in 2019, and 5,563 in 2020). In 2020 there were two diagnostic drops: -37.2% (March-May), -15.8% (October-December). Early-stage at presentation (76.4% vs. 74.4%, p = 0.0013), conserving surgery (71.0% vs. 67.0%, p < 0.0001), chemotherapy (86.2% vs. 53.4%, p < 0.0001), and radiotherapy (65.7% vs. 42.1%, p < 0.0001) decreased in 2020 compared to 2019. COVID-19 occurred in 250 patients (4...
July 20, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37481795/analysis-of-the-association-of-her-2-low-carcinomas-and-pam50-assay-in-hormone-receptor-positive-early-stage-breast-cancer
#19
JOURNAL ARTICLE
Santiago Terán, Manuel Alva, Pablo Tolosa, Macarena Rey-Cárdenas, Ainhoa Madariaga, Laura Lema, Yolanda Ruano, Luis Manso, Eva Ciruelos, Rodrigo Sánchez-Bayona
BACKGROUND: HER2-low has emerged as a new predictive biomarker in metastatic breast cancer. However, its prognostic value in early-stage carcinomas needs to be revisited. We aimed to evaluate the association of HER2-low carcinomas with PAM50 risk groups combined with clinicopathological variables in early breast cancer. METHODS: We conducted a retrospective analysis of 332 patients with early-stage breast cancer that underwent PAM50 signature analysis between 2015 and 2021at Hospital Universitario 12 de Octubre (Madrid, Spain)...
July 19, 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/37544090/-partbrecon-study-a-uk-multicentre-retrospective-cohort-study-to-assess-outcomes-following-partial-breast-reconstruction-with-chest-wall-perforator-flaps
#20
JOURNAL ARTICLE
A Agrawal, L Romics, D Thekkinkattil, M Soliman, M Kaushik, P Barmpounakis, C Mortimer, C A Courtney, A Goyal, E Garreffa, A Carmichael, R A Lane, C Rutherford, B Kim, R Achuthan, V Pitsinis, S Goh, B Ray, K Grover, R Vidya, J Murphy
BACKGROUND: Partial breast reconstruction with a pedicled chest wall perforator flap (CWPF) enables breast conservation in a higher tumour: breast volume ratio scenario. Since there is limited evidence, this retrospective cohort study aimed to ascertain immediate (30-days) and medium-term (follow-up duration) surgical outcomes. METHODS: STROBE-compliant protocol ascertained CWPF outcomes between March 2011-March 2021. UK centres known to perform CWPF were invited to participate if they performed at least 10 cases...
July 17, 2023: Breast: Official Journal of the European Society of Mastology
journal
journal
31139
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.